A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).

Li, Jin; Qin, Shukui; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Rui-Hua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Shu, Yonggian; Yuan, Ying; Xu, Nong; Zhou, Jianfeng; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Fan, Songhua; Hua, Ye; Su, Weiguo

doi:10.1200/JCO.2017.35.15_suppl.3508

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO).

作者：Li, Jin; Qin, Shukui; Bai, Yuxian; Deng, Yanhong; Yang, Lei; Xu, Rui-Hua; Chen, Zhendong; Zhong, Haijun; Pan, Hongming; Shu, Yonggian; Yuan, Ying; Xu, Nong; Zhou, Jianfeng; Liu, Tianshu; Ma, Dong; Wu, Changping; Cheng, Ying; Fan, Songhua; Hua, Ye; Su, Weiguo

来源：53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Chicago, IL, 2017-06-02 To 2017-06-07.

DOI：10.1200/JCO.2017.35.15_suppl.3508